Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1.

Ausems CRM, Raaijmakers RHL, van den Broek WJAA, Willemse M, van Engelen BGM, Wansink DG, van Bokhoven H.

Mol Ther Methods Clin Dev. 2019 Sep 12;15:120-132. doi: 10.1016/j.omtm.2019.09.002. eCollection 2019 Dec 13.

2.

CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.

van Agtmaal EL, André LM, Willemse M, Cumming SA, van Kessel IDG, van den Broek WJAA, Gourdon G, Furling D, Mouly V, Monckton DG, Wansink DG, Wieringa B.

Mol Ther. 2017 Jan 4;25(1):24-43. doi: 10.1016/j.ymthe.2016.10.014. Epub 2017 Jan 4.

3.

A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.

Gudde AE, González-Barriga A, van den Broek WJ, Wieringa B, Wansink DG.

Hum Mol Genet. 2016 Apr 15;25(8):1648-62. doi: 10.1093/hmg/ddw042. Epub 2016 Feb 16.

4.

Half-time bone scintigraphy in prostate and breast cancer patients.

Grootjans W, Serém SJ, Gomes MI, Heijmen L, Bulten BF, Mijnheere EP, Hermsen R, van den Broek WJ.

Q J Nucl Med Mol Imaging. 2018 Sep;62(3):303-312. doi: 10.23736/S1824-4785.16.02830-2. Epub 2016 Feb 16.

PMID:
26883516
5.

Cell membrane integrity in myotonic dystrophy type 1: implications for therapy.

González-Barriga A, Kranzen J, Croes HJ, Bijl S, van den Broek WJ, van Kessel ID, van Engelen BG, van Deutekom JC, Wieringa B, Mulders SA, Wansink DG.

PLoS One. 2015 Mar 23;10(3):e0121556. doi: 10.1371/journal.pone.0121556. eCollection 2015.

6.

Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13915-20. doi: 10.1073/pnas.0905780106. Epub 2009 Aug 10.

8.

Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.

Savonije JH, van Groeningen CJ, van den Broek WJ, Rentinck ME, Corstens FH, Gundy C, Giaccone G, Marx JJ.

Cancer Invest. 2006 Oct;24(6):562-6.

PMID:
16982459
9.

Fen1 does not control somatic hypermutability of the (CTG)(n)*(CAG)(n) repeat in a knock-in mouse model for DM1.

van den Broek WJ, Nelen MR, van der Heijden GW, Wansink DG, Wieringa B.

FEBS Lett. 2006 Oct 2;580(22):5208-14. Epub 2006 Sep 5.

10.

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.

Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s.

11.

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

J Clin Oncol. 2005 Sep 20;23(27):6540-8.

PMID:
16170161
12.

The Nuclear Medicine Technologist in Europe - current status and future perspective.

van den Broek WJ.

Nucl Med Rev Cent East Eur. 2003;6(2):135-7. No abstract available.

PMID:
14737729
13.

Quantitative detection of peripheral thyroglobulin mRNA has limited clinical value in the follow-up of thyroid cancer patients.

Span PN, Sleegers MJ, van den Broek WJ, Ross HA, Nieuwlaat WA, Hermus AR, Sweep CG.

Ann Clin Biochem. 2003 Jan;40(Pt 1):94-9.

PMID:
12542917
14.

Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins.

van den Broek WJ, Nelen MR, Wansink DG, Coerwinkel MM, te Riele H, Groenen PJ, Wieringa B.

Hum Mol Genet. 2002 Jan 15;11(2):191-8.

PMID:
11809728
15.

Clinical significance of low cobalamin levels in older hospital patients.

van Asselt DZ, Blom HJ, Zuiderent R, Wevers RA, Jakobs C, van den Broek WJ, Lamers CB, Corstens FH, Hoefnagels WH.

Neth J Med. 2000 Aug;57(2):41-9.

PMID:
10924940
16.

Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.

Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH.

J Nucl Med. 2000 Apr;41(4):643-6.

17.

Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.

Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s.

PMID:
10541374
18.

Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.

Huysmans DA, Buijs WC, van de Ven MT, van den Broek WJ, Kloppenborg PW, Hermus AR, Corstens FH.

J Nucl Med. 1996 Dec;37(12):2072-9.

19.

Free and protein-bound cobalamin absorption in healthy middle-aged and older subjects.

van Asselt DZ, van den Broek WJ, Lamers CB, Corstens FH, Hoefnagels WH.

J Am Geriatr Soc. 1996 Aug;44(8):949-53.

PMID:
8708306
20.

Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-deficient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice.

van Ree JH, van den Broek WJ, Dahlmans VE, Wieringa B, Frants RR, Havekes LM, Hofker MH.

Atherosclerosis. 1995 Nov;118(1):165-7. No abstract available.

PMID:
8579626
21.

Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members.

van Ree JH, van den Broek WJ, van der Zee A, Dahlmans VE, Wieringa B, Frants RR, Havekes LM, Hofker MH.

Hum Mol Genet. 1995 Aug;4(8):1403-9.

PMID:
7581381
22.

Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake.

Oyen WJ, Mudde AH, van den Broek WJ, Corstens FH.

J Nucl Med. 1995 Apr;36(4):613-5.

23.

Increased response to cholesterol feeding in apolipoprotein C1-deficient mice.

van Ree JH, Hofker MH, van den Broek WJ, van Deursen JM, van der Boom H, Frants RR, Wieringa B, Havekes LM.

Biochem J. 1995 Feb 1;305 ( Pt 3):905-11.

24.

Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding.

van Ree JH, Gijbels MJ, van den Broek WJ, Hofker MH, Havekes LM.

Atherosclerosis. 1995 Jan 20;112(2):237-43.

PMID:
7772082
25.

Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice.

van Ree JH, van den Broek WJ, Dahlmans VE, Groot PH, Vidgeon-Hart M, Frants RR, Wieringa B, Havekes LM, Hofker MH.

Atherosclerosis. 1994 Nov;111(1):25-37.

PMID:
7840811
26.

Zinc exchange by blood cells in nearly physiologic standard conditions.

Naber TH, van den Hamer CJ, van den Broek WJ, Roelofs H.

Biol Trace Elem Res. 1994 Oct-Nov;46(1-2):29-50.

PMID:
7888283
27.

The in-vitro uptake of zinc by blood cells in rats with long-term inflammatory stress.

Naber TH, Heymer F, Van Den Hamer CJ, Van Den Broek WJ, Jansen JB.

Clin Nutr. 1994 Aug;13(4):247-55.

PMID:
16843393
28.

Magnetic resonance imaging for volume estimation of large multinodular goitres: a comparison with scintigraphy.

Huysmans DA, de Haas MM, van den Broek WJ, Hermus AR, Barentsz JO, Corstens FH, Ruijs SH.

Br J Radiol. 1994 Jun;67(798):519-23.

PMID:
8032803
29.

Zinc uptake by blood cells of rats in zinc deficiency and inflammation.

Naber TH, van den Hamer CJ, van den Broek WJ, van Tongeren JH.

Biol Trace Elem Res. 1992 Nov;35(2):137-52.

PMID:
1280980
30.

Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice.

Massuger LF, Boerman OC, Corstens FH, Verheijen RH, Claessens RA, Poels LG, van den Broek WJ, Kenemans P.

Anticancer Res. 1991 Nov-Dec;11(6):2051-7.

PMID:
1776839
31.

Determination of individual human faecal bile acids by gas-liquid chromatography after enzymatic deconjugation and simultaneous solvolysis and methylation using dimethoxypropane.

van Faassen A, Nagengast FM, Hectors M, van den Broek WJ, Huijbregts AW, van der Werf SD, van Berge Henegouwen GP, van Tongeren JH.

Clin Chim Acta. 1985 Oct 31;152(1-2):231-9. No abstract available.

PMID:
4053402
32.

99mTc-pertechnetate uptake measurement in the rabbit knee-joint. II. Kinetics of 99mTcO-4 in normal and arthritic rabbit knee-joints.

van Beusekom HJ, van de Putte LB, Buijs WC, van den Broek WJ, van den Berg WB.

Scand J Rheumatol. 1983;12(1):59-63.

PMID:
6300997
33.

99mTc-pertechnetate uptake after total knee replacement in rheumatoid arthritis.

Boerbooms AM, van den Broek WJ, van Rens TJ, van de Putte LB.

Acta Orthop Scand. 1982 Feb;53(1):125-9.

PMID:
6278816
34.

Antigen-induced arthritis: inflammation and antigen handling after two different doses of intra-articularly injected antigen.

van Beusekom HJ, van de Putte LB, van den Berg WB, van den Broek WJ.

Immunology. 1982 Feb;45(2):193-8.

35.

Detection and quantification of experimental joint inflammation in mice by measurement of 99mTc-pertechnetate uptake.

Kruijsen MW, van den Berg WB, van de Putte LB, van den Broek WJ.

Agents Actions. 1981 Dec;11(6-7):640-2.

PMID:
6280467
36.
37.

99mTc-pertechnetate uptake measurement in the rabbit knee-joint.

van Beusekom HJ, van den Broek WJ, van de Putte LB, Buys WC, van den Berg WB.

J Rheumatol. 1981 Jan-Feb;8(1):31-9.

PMID:
6260946
38.

Antigen-induced arthritis: inflammation and antigen handling.

van Beusekom HJ, van de Putte LB, van den Berg WB, van den Broek WJ.

Scand J Rheumatol Suppl. 1981;40:37-41.

PMID:
6100916
39.

Protoplasts from Aspergillus nidulans.

van den Broek WJ, Stunnenberg HG, Wennekes LM.

Microbios. 1979;26(104):115-28.

PMID:
399317
40.

Pyridine-nucleotide transhydrogenase. 5. Kinetic studies on transhydrogenase from Azotobacter vinelandii.

Van den Broek WJ, Veeger C.

Eur J Biochem. 1971 Dec 22;24(1):72-82. No abstract available.

41.

Pyridine-nucleotide transhydrogenase. 4. Studies on the reductive mechanism of transhydrogenase from Azotobacter vinelandii.

Van den Broek WJ, Veeger C.

Eur J Biochem. 1971 Dec 22;24(1):63-71. No abstract available.

42.

Pyridine-nucleotide transhydrogenase. 3. Effect of NADP+ on the spectral properties of transhydrogenase from Azotobacter vinelandii.

Van den Broek WJ, Santema JS, Veeger C.

Eur J Biochem. 1971 Dec 22;24(1):55-62. No abstract available.

43.

Pyridine-nucleotide transhydrogenase. 2. Electron-microscopic studies on the transhydrogenase from Azotobacter vinelandii.

Van den Broek WJ, Van Breemen JF, Van Bruggen EF, Veeger C.

Eur J Biochem. 1971 Dec 22;24(1):46-54. No abstract available.

44.

Pyridine-nucleotide transhydrogenase. 1. Isolation, purification and characterisation of the transhydrogenase from Azotobacter vinelandii.

Van den Broek WJ, Santema JS, Wassink JH, Veeger C.

Eur J Biochem. 1971 Dec 22;24(1):31-45. No abstract available.

Supplemental Content

Loading ...
Support Center